Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Illinois: - University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
- University of Chicago Medicine-Orland Park — Orland Park, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Illinois: - Research Site — Chicago, Illinois
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Sites in Illinois: - The University of Chicago Medical Center /ID# 255674 — Chicago, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Illinois: - Northwestern University — Chicago, Illinois
- University of Illinois Health Outpatient Care Center — Chicago, Illinois
- The Duchossois Center for Advanced Medicine — Chicago, Illinois
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois: - Orchard Healthcare Research Inc. — Skokie, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unr…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT05168163
Sites in Illinois: - University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Carle Cancer Center NCI Community Oncology Research Program — Urbana, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in Illinois: - Local Institution - 0107 — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The s…
Sponsor: Iterion Therapeutics
NCT ID: NCT05797805
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Illinois: - Exelixis Clinical Site #26 — Chicago, Illinois
Phase 1 Recruiting Industry
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT…
Sponsor: Alnylam Pharmaceuticals
NCT ID: NCT06600321
Sites in Illinois: - Clinical Trial Site — Chicago, Illinois
Phase 1 Recruiting Industry
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events a…
Sponsor: AbbVie
NCT ID: NCT06858813
Sites in Illinois: - University of Chicago Medical Center /ID# 270517 — Chicago, Illinois
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Illinois: - Massive Bio SYNERGY-AI site — Chicago, Illinois
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Illinois: - Rush-Copley Cancer Care Center — Aurora, Illinois
- Rush-Copley Healthcare Center — Yorkville, Illinois
Recruiting Industry
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristic…
Sponsor: HistoSonics, Inc.
NCT ID: NCT06486454
Sites in Illinois: - RUSH University Medical Center — Chicago, Illinois
- University of Chicago — Chicago, Illinois
Recruiting Industry
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multi…
Sponsor: AstraZeneca
NCT ID: NCT06252753
Sites in Illinois: - Research Site — Evergreen Park, Illinois
- Research Site — Hinsdale, Illinois
Phase 4 Recruiting Academic/Other
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection…
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT06084234
Sites in Illinois: - Northwestern University — Chicago, Illinois
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
- Methodist Medical Center of Illinois — Peoria, Illinois
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Illinois: - Research Site — O'Fallon, Illinois
NA Recruiting Academic/Other
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary live…
Sponsor: Maastricht University
NCT ID: NCT06914648
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
Recruiting Academic/Other
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The fir…
Sponsor: Northwestern University
NCT ID: NCT04390724
Sites in Illinois: - Northwestern University — Chicago, Illinois
Recruiting Academic/Other
The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal…
Sponsor: University of Chicago
NCT ID: NCT01416714
Sites in Illinois: - The University of Chicago — Chicago, Illinois